NanoenTekInc (039860) - Total Liabilities
Based on the latest financial reports, NanoenTekInc (039860) has total liabilities worth ₩5.42 Billion KRW (≈ $3.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 039860 cash flow metrics to assess how effectively this company generates cash.
NanoenTekInc - Total Liabilities Trend (2007–2024)
This chart illustrates how NanoenTekInc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of NanoenTekInc to evaluate the company's liquid asset resilience ratio.
NanoenTekInc Competitors by Total Liabilities
The table below lists competitors of NanoenTekInc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PPX Mining Corp
V:PPX
|
Canada | CA$64.40 Million |
|
Fiamma Holdings Bhd
KLSE:6939
|
Malaysia | RM149.92 Million |
|
Om Holdings Ltd
AU:OMH
|
Australia | AU$407.98 Million |
|
Sakar Healthcare Limited
NSE:SAKAR
|
India | Rs1.45 Billion |
|
KJTS
KLSE:0293
|
Malaysia | RM28.47 Million |
|
United Paper Public Company Limited
BK:UTP
|
Thailand | ฿467.78 Million |
|
HomesToLife Ltd
NASDAQ:HTLM
|
USA | $86.58 Million |
|
EQL PHARMA AB
F:7JK
|
Germany | €543.76 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down NanoenTekInc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is NanoenTekInc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoenTekInc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoenTekInc (2007–2024)
The table below shows the annual total liabilities of NanoenTekInc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩5.01 Billion ≈ $3.40 Million |
+0.54% |
| 2023-12-31 | ₩4.99 Billion ≈ $3.38 Million |
-11.42% |
| 2022-12-31 | ₩5.63 Billion ≈ $3.81 Million |
-44.35% |
| 2021-12-31 | ₩10.11 Billion ≈ $6.85 Million |
+38.01% |
| 2020-12-31 | ₩7.33 Billion ≈ $4.97 Million |
+30.55% |
| 2019-12-31 | ₩5.61 Billion ≈ $3.80 Million |
-19.93% |
| 2018-12-31 | ₩7.01 Billion ≈ $4.75 Million |
-62.38% |
| 2017-12-31 | ₩18.64 Billion ≈ $12.63 Million |
-7.41% |
| 2016-12-31 | ₩20.13 Billion ≈ $13.64 Million |
+40.99% |
| 2015-12-31 | ₩14.28 Billion ≈ $9.68 Million |
+84.03% |
| 2014-12-31 | ₩7.76 Billion ≈ $5.26 Million |
-63.45% |
| 2013-12-31 | ₩21.23 Billion ≈ $14.38 Million |
-1.09% |
| 2012-12-31 | ₩21.46 Billion ≈ $14.54 Million |
+2.68% |
| 2011-12-31 | ₩20.90 Billion ≈ $14.16 Million |
+193.93% |
| 2007-12-31 | ₩7.11 Billion ≈ $4.82 Million |
-- |
About NanoenTekInc
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a resid… Read more